Data from a preclinical study show that AR-42, an experimental drug, may stop cachexia associated with advanced cancers and restore muscle health, according to a study in the Journal of the National Cancer Institute. Read more and read the study abstract.
© 2020 HealthCom Media
All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder